New Clot-Busting drug could change heart attack care
NCT ID NCT06769256
First seen Jun 04, 2026 · Last updated Jun 19, 2026 · Updated 6 times
Summary
This study compares two drugs given directly into the heart arteries during a heart attack: rhTNK-tPA, a clot dissolver, and tirofiban, a blood thinner. Researchers will enroll 300 patients with severe blockages to see which drug restores blood flow better and causes fewer bleeding problems. The goal is to find a safer, more effective way to treat heart attacks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION (STEMI) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fuwai Central China Cardiovascular Hospital
RECRUITINGZhengzhou, Henan, China
Contact Phone: •••-•••-••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
rhTNK-tPA (a clot-dissolving drug) and tirofiban (a blood-thinning drug)
What this could lead to
If rhTNK-tPA works as well as tirofiban, it could offer another option to restore blood flow after a heart attack, potentially reducing heart damage.
What could go wrong
This is a mid-stage trial with only 300 patients, so results may not apply to everyone. Both drugs carry a risk of bleeding, and rhTNK-tPA might not prove as effective or safe as hoped.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.